CN104000800A - Asenapine maleate oral instant membrane and making method thereof - Google Patents
Asenapine maleate oral instant membrane and making method thereof Download PDFInfo
- Publication number
- CN104000800A CN104000800A CN201410173240.1A CN201410173240A CN104000800A CN 104000800 A CN104000800 A CN 104000800A CN 201410173240 A CN201410173240 A CN 201410173240A CN 104000800 A CN104000800 A CN 104000800A
- Authority
- CN
- China
- Prior art keywords
- maleic acid
- hypromellose
- asenapine
- oral instant
- instant membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an Asenapine maleate oral instant membrane used for treating adult schizophrenia, chronic severe brain dysfunction and type I bipolar disorder, and a making method thereof. The above dosage form has the advantages of convenient administration, administration without water, rapid dissolving in the oral cavity, restriction or complete prevention of the removal of a medicine by a schizophrenia patient, and improvement of the compliance f the patient. The main drug content of the dosage form made through the making method can reach the unit dosage of Asenapine maleate, and the dosage form has the characteristics of drug loading uniformity, good appearance and good stability. In the production process, the technology is simple, the cost is low, and almost no dust is generated.
Description
Technical field
The present invention relates to a kind of chemical drugs and preparation method thereof, the medicine particularly relating to is atypical antipsychotic drugs maleic acid asenapine oral instant membrane and preparation method thereof.
Background technology
Along with social high speed development, people's work and life stress are increasing, cause increasing of mental sickness.According to statistics, mental sickness has surpassed the diseases such as cardiovascular and cerebrovascular vessel, respiratory system and malignant tumor in the rank of the total burden of China's disease, leaps to the umber one.The number that all kinds of mental sickness are suffered from by China accounts for 7.7% of about total population.
Schizophrenia be a kind ofly continue, chronic great mental sickness conventionally, be the most serious a kind of in psychosis.According to statistics, global schizophrenic's number is up to 2,400 ten thousand, and China approximately has 1,000 ten thousand schizophrenics at present.In addition, WHO estimates that schizoid lifelong prevalence is 3.8 ‰-8.4 ‰, and domestic 12 regional Epidemiological studys show the lifelong prevalence 5.6 ‰ of psychosis Split disease.This disease is a kind of chronic disease, and its high relapse rate, high disability rate are directly to cause the poor He Qi of patient family due to illness and poor immediate cause is the mental sickness of state key control.At present treatment schizophrenia is when selecting medicine, should vary with each individual and different because of symptom, and from the direction of Clinical Psychological Medicine development, be that the positive or negative symptoms all should first-selected atypical antipsychotic agents.World mental health association treatment algorithm is recommended, and the atypical antipsychotic of generally usining is selected as first-line drug.And aspect the positive symptom and negative symptoms control, maleic acid asenapine is brand-new atypical antipsychotic, can be used as first-line drug, independent or auxiliary treatment.
Schizophrenia is also that a kind of cause of disease is not by clear and definite mental sickness.At present, Drug therapy is schizoid preferred manner, and atypical antipsychotic is the schizoid choice drug for the treatment of.At present, the conventional atypical antipsychotic of China has 5 kinds, is respectively: olanzapine, risperidone, Quetiapine, Aripiprazole and Ziprasidone.Maleic acid asenapine, as novel atypical antipsychotic, is first medicine that simultaneously obtains treatment adult's schizophrenia and two kinds of indications of adult's the first type manic depression.This medicine is a kind of brand-new important therapy, and for doctor and patient, many again available treatments are selected.
Take the Traditional antipsychotics that chlorpromazine and haloperidol be representative, for the positive symptom, have certain curative effect, but to negative symptoms weak curative effect.And with the extrapyramidal symptoms, a few patients there will be tardive dyskinesia and pernicious symptom.By contrast, atypical antipsychotic class medicine is afterwards more extensive than conventional medicament curative effect, and untoward reaction is little, so atypical antipsychotic is extensively sent out and is applied to clinically, replaces conventional medicament.Maleic acid asenapine is latest model atypical antipsychotic, and with olanzapine, risperidone etc. are compared, and indication is more extensive, and toxic and side effects is lower, and can be for the emergency treatment of adult patients.Have broad application prospects and good clinical efficacy.
The research and development of maleic acid asenapine Shi You Schering Plough company, U.S. FDA is in approval listing on July 30th, 2009.This medicine belongs to atypical antipsychotic, is used for the treatment of adult's schizophrenia, chronic severe disordered brain function and I type bipolar disorder.The problem of schizophrenic's ubiquity compliance, patient is Refuse to take medicine usually, Tibetan medicine and tell medicine phenomenon and usually occur in oral cavity.So conventional Tablet and Capsula agent cannot play a role often, and affect the treatment of disease.At this moment, just need a kind of pharmaceutical dosage form to be easily used for the treatment of schizophrenia, avoid occurring the problems referred to above.
Oral instant membrane is with regard to a kind of dosage form that can well improve patient compliance.It is prepared and obtained by hydrophilic high molecular material, without using water delivery service.Maleic acid asenapine is a kind of medicine by buccal absorption, is prepared into oral instant membrane and can improves medicine in intraoral absorbability.On producing, the cost of oral instant membrane is far below listing lyophilizing oral cavity disintegration tablet; Lyophilizing oral cavity disintegration tablet describes easily destroyed in packing, storage and transportation China and foreign countries, and oral instant membrane has well solved this problem.How preparing physical property good, and guarantee dispersion of medicine and stable membrane, is the problem that we need to solve.
Summary of the invention
The object of the present invention is to provide a kind of dosage form that can effectively address the above problem.Oral instant membrane can be at intraorally rapidly disintegrating, and taking convenience, has improved patient's compliance, and bioavailability is higher, and the product that goes on the market, and has reduced production cost, has simplified production stage.Meanwhile, be also more conducive to packing, store and transportation.
Maleic acid asenapine oral instant membrane of the present invention, it is as follows that it comprises component:
Maleic acid asenapine
Two kinds of high molecular material compositions
Plasticizer
Correctives
Disintegrating agent
Other adjuvants
Two kinds of described high molecular material compositions are selected from a group in maltodextrin and hypromellose, polyvinyl alcohol and hyaluronic acid, hypromellose and hyaluronic acid, polyvinylpyrrolidone and hypromellose and polyvinyl alcohol and hypromellose.
In described two kinds of preferred maltodextrins of high molecular material compositions and hypromellose, polyvinyl alcohol and hyaluronic acid, hypromellose and hyaluronic acid one group.
Described plasticizer is selected from one or more in glycerol, propylene glycol, Polyethylene Glycol and triethyl citrate.
Described disintegrating agent is selected from one or more in pregelatinized Starch, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose and carboxymethyl starch sodium.
Described correctives comprises one or more in sweeting agent and aromatic;
Described sweeting agent is selected from one or more in mannitol, sucralose, Aspartane and sucrose;
Described aromatic is selected from Fructus Citri tangerinae essence, black currant essence, a kind of in Oleum menthae, Oleum menthae and oleum Citri sinensis or more than.
Other described adjuvants comprise coloring agent, opacifier, stabilizing agent and antiseptic.
Maleic acid asenapine oral instant membrane is preferably as follows the component of percentage by weight:
Maleic acid asenapine: 10% ~ 30%
Two kinds of high molecular material compositions: 60% ~ 80%
Plasticizer: 5% ~ 20%
Disintegrating agent: 0 ~ 3%
Correctives: 0 ~ 25%
Other adjuvants: 0 ~ 5%
Described maleic acid asenapine oral instant membrane, can disintegrate fast and dissolving in water, within 60 seconds in 25 ℃ of water, with interior, can dissolve completely.
Described maleic acid asenapine has good toughness, and the tensile property index of its oral instant membrane extends percentage ratio and is greater than 10%.(extending percentage ratio E%=(L-L0)/L0*100%, L is membrane length after stretching, L0 is raw footage)
Described maleic acid asenapine oral instant membrane, its drug loading accurately and homogeneous, can reach the unit dose of maleic acid asenapine.
Another object of the present invention has been to provide a kind of method of preparing maleic acid asenapine oral instant membrane, can prepare rapid release, and the maleic acid oral instant membrane of uniform content.This preparation method comprises the following steps:
(1) ethanol of use 30% ~ 60%, as solvent, dissolves macromolecule filming material compositions and plasticizer, makes the macromolecule glue that blade coating is used;
(2) maleic acid asenapine, correctives, disintegrating agent and other adjuvants are added in the glue of step (1), be stirred to dissolving;
(3), by above-mentioned glue vacuum outgas, blade coating is on back plastic lining form, dry, and membrane is peeled off from backing film, cuts into certain size, packs and get final product.
Another object of the present invention is, provides a kind of maleic acid asenapine oral instant membrane to be used for the treatment of to be grown up the purposes of schizophrenia, chronic severe disordered brain function and I type bipolar disorder.
Maleic acid oral instant membrane of the present invention is a kind of non-Mucoadhesive membrane, and when it enters oral cavity, membrane can stick in oral mucosa and dissolve fast; Main maleic acid asenapine absorbs by oral mucosa.Described oral instant membrane has the similar bioavailability of maleic acid asenapine Sublingual oral cavity disintegration tablet.
After maleic acid asenapine oral instant membrane entrance, be attached on oral mucosa, and dissolve fast, thereby limit or prevent that schizophrenic from taking out medicine completely.So this dosage form can be improved the compliance of administration greatly.In addition, with respect to listing lyophilizing oral cavity disintegration tablet, membrane cost is low, packing and convenient transportation.
The specific embodiment
For technical scheme of the present invention is described better, spy provides following examples, but the present invention is not limited in following instance.
Embodiment 1:
2000 of recipe quantities (5mg specification) or 1000 (10mg specification)
Prescription:
Maleic acid asenapine 10g
Hyaluronic acid 1.0g
Hypromellose E15LV 50g
Propylene glycol 12g
Sucralose 0.64g
Medical dehydrated alcohol 200g
Distilled water 200g
Preparation method:
Step 1: take 1.0g hyaluronic acid, 50g hypromellose E5LV and 12g propylene glycol, be placed in appropriate containers adds 200g distilled water and 200g dehydrated alcohol in container, is stirred to dissolving homogeneous;
Step 2: take 10g maleic acid asenapine, drop in the glue of step 1, continue to be stirred to dissolving homogeneous;
Step 3: take 0.64g tri-filter sucrose, add in the glue of step 2, be stirred to it and dissolve completely, standing 6 hours of vacuum is degassed; By the glue after degassed, blade coating is on back plastic lining form, and 60 ~ 70 ℃ dry, then, membrane peeled off from backing film, cuts into certain size, packs and get final product.
Embodiment 2:
2000 of recipe quantities (5mg specification) or 1000 (10mg specification)
Prescription:
Maleic acid asenapine 10g
Hyaluronic acid 1.6g
Hypromellose E5LV 60g
Glycerol 10g
Sucralose 0.5g
Oleum menthae 0.5g
Medical dehydrated alcohol 200g
Distilled water 200g
Preparation method:
Step 1: take 60g hypromellose E5LV and 1.6g hyaluronic acid, be placed in suitable container, add the medical dehydrated alcohol of 200ml and 200ml distilled water, be heated to 60 ℃, overtime work, to dissolving completely, is cooled to room temperature; ;
Step 2: take 10g maleic acid asenapine and 10g glycerol, drop in the glue of step 1, continue to be stirred to dissolving homogeneous;
Step 3: take 0.5g tri-filter sucrose and 0.5g Oleum menthae, add in the glue of step 2, be stirred to it and dissolve completely, standing 6 hours of vacuum is degassed; By the glue after degassed, blade coating is on back plastic lining form, and 60 ~ 70 ℃ dry, then, membrane peeled off from backing film, cuts into certain size, packs and get final product.
Embodiment 3:
2000 of recipe quantities (5mg specification) or 1000 (10mg specification)
Prescription:
Maleic acid asenapine 10g
Hyaluronic acid 1.0g
Polyvinyl alcohol 60g
Propylene glycol 12g
Sucralose 0.5g
Fructus Citri tangerinae essence 0.5g
Medical dehydrated alcohol 200g
Distilled water 200g
Preparation method:
Step 1: take 60g polyvinyl alcohol and 1.0g hyaluronic acid, be placed in suitable container, add the medical dehydrated alcohol of 200ml and 200ml distilled water, be heated to 60 ℃, overtime work, to dissolving completely, is cooled to room temperature;
Step 2: take 10g maleic acid asenapine and 12g propylene glycol, drop in the glue of step 1, continue to be stirred to dissolving homogeneous;
Step 3: take 0.5g tri-filter sucrose and 0.5g Fructus Citri tangerinae essence, add in the glue of step 2, be stirred to it and dissolve completely, standing 6 hours of vacuum is degassed; By the glue after degassed, blade coating is on back plastic lining form, and 60 ~ 70 ℃ dry, then, membrane peeled off from backing film, cuts into certain size, packs and get final product.
Embodiment 4:
2000 of recipe quantities (5mg specification) or 1000 (10mg specification)
Prescription:
Maleic acid asenapine 10g
Maltose cyclodextrin 10g
Hypromellose E5LV 50g
Glycerol 12g
Sucralose 0.3g
Oleum menthae 0.5g
Medical dehydrated alcohol 200g
Distilled water 200g
Preparation method:
Step 1: take 10g maltose cyclodextrin and 50g hypromellose E5LV, be placed in suitable container, add the medical dehydrated alcohol of 200g and 200g distilled water, be heated to 60 ℃, overtime work, to dissolving completely, is cooled to room temperature;
Step 2: take 10g maleic acid asenapine and 12g glycerol, drop in the glue of step 1, continue to be stirred to dissolving homogeneous;
Step 3: take 0.3g sucralose and 0.5g Oleum menthae, add in the glue of step 2, be stirred to it and dissolve completely, standing 6 hours of vacuum is degassed; By the glue after degassed, blade coating is on back plastic lining form, and 60 ~ 70 ℃ dry, then, membrane peeled off from backing film, cuts into certain size, packs and get final product.
Embodiment 5:
2000 of recipe quantities (5mg specification) or 1000 (10mg specification)
Prescription:
Maleic acid asenapine 10g
Maltose cyclodextrin 20g
Hypromellose E5LV 40g
Glycerol 10g
Aspartane 0.5g
Oleum menthae 0.5g
Medical dehydrated alcohol 200g
Distilled water 200g
Preparation method:
Step 1: take 20g maltose cyclodextrin and 40g hypromellose E5LV, be placed in suitable container, add the medical dehydrated alcohol of 200ml and 200ml distilled water, be heated to 60 ℃, overtime work, to dissolving completely, is cooled to room temperature;
Step 2: take 10g maleic acid asenapine and 10g glycerol, drop in the glue of step 1, continue to be stirred to dissolving homogeneous;
Step 3: take 0.5g Aspartane and 0.5g Oleum menthae, add in the glue of step 2, be stirred to it and dissolve completely, standing 6 hours of vacuum is degassed; By the glue after degassed, blade coating is on back plastic lining form, and 60 ~ 70 ℃ dry, then, membrane peeled off from backing film, cuts into certain size, packs and get final product.
Test example 6: the mensuration of disintegration
The membrane that embodiment 1 ~ 5 is prepared, cuts into the size of 1.5*3cm, carries out disintegration time mensuration.
Get 6 1.5*3cm membrane, be laid in respectively in dry culture dish, drip the distilled water of 25 ℃ on membrane, and start timing simultaneously with dropper, water stops timing during through membrane.The time of surveying is the film disintegrates time.
Measurement result following (meansigma methods):
Embodiment 1:25s
Embodiment 2:28s
Embodiment 3:22s
Embodiment 4:23s
Embodiment 5:30s
As seen from the above table, the membrane that described embodiment obtains can disintegrate in water fast, rapid delivery of pharmaceuticals.
Test example 7: Erichsen test
Adopt universal material experiment instrument (Instron 3365), film is cut to about 2 cm*0.5 cm sizes (under 43%RH humidity balance one week), draw speed 5 mmmin-1, every membrane is all by longitudinal stretching, until film fracture.Calculating prolongation percentage ratio, elastic modelling quantity carry out the tensile property of evaluated for film.
The sample of embodiment 1 ~ 5 preparation, gets respectively 6 do experiment (1.5*3cm), measures and extends percentage result following (meansigma methods):
Embodiment 1:15%
Embodiment 2:22%
Embodiment 3:12%
Embodiment 4:18%
Embodiment 5:21%
As seen from the above table, the tensile property index prolongation percentage ratio of the membrane of described embodiment 1 ~ 5 preparation is all greater than 10%.
Claims (9)
1. a maleic acid asenapine oral instant membrane, is characterized in that, comprises the component of following percentage by weight:
Maleic acid asenapine: 5% ~ 40%
Two kinds of macromolecule filming material compositionss: 50% ~ 90%
Plasticizer: 3% ~ 30%
Disintegrating agent: 0 ~ 20%
Correctives: 0 ~ 25%
Other adjuvants: 0 ~ 5%.
2. maleic acid asenapine oral instant membrane according to claim 1, is characterized in that:
Two kinds of described macromolecule filming material compositionss are selected from a group in maltodextrin and hypromellose, polyvinyl alcohol and hyaluronic acid, hypromellose and hyaluronic acid, polyvinylpyrrolidone and hypromellose and polyvinyl alcohol and hypromellose;
Described plasticizer be selected from glycerol, propylene glycol, Polyethylene Glycol and triethyl citrate one or more;
Described disintegrating agent be selected from pregelatinized Starch, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose and carboxymethyl starch sodium one or more;
Described correctives comprises sweeting agent and aromatic, and wherein sweeting agent is selected from mannitol, sucralose, Aspartane and sucrose, and aromatic is selected from Fructus Citri tangerinae essence, black currant essence, Oleum menthae, Oleum menthae and oleum Citri sinensis;
Other described adjuvants comprise coloring agent, opacifier, stabilizing agent and antiseptic.
3. according to the maleic acid asenapine oral instant membrane described in claim 1,2, its feature comprises the component of following weight ratio:
Maleic acid asenapine: 10% ~ 30%
Two kinds of high molecular material compositions: 60% ~ 80%
Plasticizer: 5% ~ 20%
Disintegrating agent: 0 ~ 3%
Correctives: 0 ~ 25%
Other adjuvants: 0 ~ 5%.
4. maleic acid oral instant membrane according to claim 3, is characterized in that:
The sign viscosity of the hypromellose in two kinds of described macromolecule filming material compositionss is not more than 50cps;
Two kinds of described macromolecule filming material compositionss are selected from maltodextrin and hypromellose, polyvinyl alcohol and hyaluronic acid and hypromellose and hyaluronic acid;
Two kinds of described macromolecule filming material compositions ratios are: ratio 1:(1 ~ 5 of maltodextrin and hypromellose), polyvinyl alcohol and hyaluronic ratio (20 ~ 60): 1, hypromellose and hyaluronic ratio (30 ~ 70): 1.
5. according to the maleic acid asenapine oral instant membrane described in claim 1 ~ 4 any one, it is characterized in that, can in water, disperse fast, dissolve, within 60 seconds in 25 ℃ of water, with interior, can dissolve completely.
6. maleic acid asenapine oral instant membrane according to claim 5, is characterized in that, tensile property index extends percentage ratio and is greater than 10%.
7. prepare according to the maleic acid asenapine oral instant membrane described in claim 1 ~ 6 any one, comprise the steps:
(1) ethanol of use 30% ~ 60%, as solvent, dissolves macromolecule filming material compositions and plasticizer, makes the macromolecule glue that blade coating is used;
(2) maleic acid asenapine, correctives, disintegrating agent and other adjuvants are added in the glue of step (1), be stirred to dissolving;
(3), by above-mentioned glue vacuum outgas, blade coating is on back plastic lining form, dry, and membrane is peeled off from backing film, cuts into certain size, packs and get final product.
8. according to the maleic acid asenapine oral instant membrane described in claim 1 ~ 7 any one, it is characterized in that, the medicine specification of maleic acid asenapine is not more than 20mg.
9. according to the maleic acid asenapine oral instant membrane described in claim 1 ~ 8 any one, it is characterized in that, be used for the treatment of adult schizophrenia, chronic severe disordered brain function and I type bipolar disorder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410173240.1A CN104000800A (en) | 2014-04-28 | 2014-04-28 | Asenapine maleate oral instant membrane and making method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410173240.1A CN104000800A (en) | 2014-04-28 | 2014-04-28 | Asenapine maleate oral instant membrane and making method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104000800A true CN104000800A (en) | 2014-08-27 |
Family
ID=51361893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410173240.1A Pending CN104000800A (en) | 2014-04-28 | 2014-04-28 | Asenapine maleate oral instant membrane and making method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104000800A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201509009A1 (en) * | 2014-12-11 | 2017-02-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A thin film strip of asenapine |
| CN110354106A (en) * | 2019-08-21 | 2019-10-22 | 成都诺和晟泰生物科技有限公司 | A kind of film rapidly-soluble in the oral cavity and preparation method thereof |
| US10898449B2 (en) | 2016-12-20 | 2021-01-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112402398A (en) * | 2020-11-30 | 2021-02-26 | 北京斯利安药业有限公司 | Oral instant film of diphenhydrasol hydrochloride and preparation method thereof |
| US10952959B2 (en) | 2017-01-11 | 2021-03-23 | Ferring B.V. | Fast disintegrating pharmaceutical composition |
| US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632651A (en) * | 2009-08-31 | 2010-01-27 | 河北科技大学 | Oral instant membrane of risperidone and preparation method thereof |
| CN102048730A (en) * | 2010-12-10 | 2011-05-11 | 浙江昂利康制药有限公司 | Levamlodipine besylate composition and preparation method thereof |
| CN102657635A (en) * | 2012-05-04 | 2012-09-12 | 上海现代药物制剂工程研究中心有限公司 | Spongy asenapine sublingual film agent with micropores and preparation method thereof |
| CN102824333A (en) * | 2012-09-26 | 2012-12-19 | 苏州大学 | Oral quick-dissolving film preparation and preparation method thereof |
| CN102920683A (en) * | 2012-06-11 | 2013-02-13 | 江苏豪森药业股份有限公司 | Olanzapine oral instant membrane |
| CN103239427A (en) * | 2012-02-13 | 2013-08-14 | 刘毅佳 | Film agent for dispersing and dissolving in oral cavity |
| CN103298459A (en) * | 2010-09-23 | 2013-09-11 | 莫诺索尔克斯有限公司 | Method and system for forming a pharmaceutical product directly onto a packaging surface |
-
2014
- 2014-04-28 CN CN201410173240.1A patent/CN104000800A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632651A (en) * | 2009-08-31 | 2010-01-27 | 河北科技大学 | Oral instant membrane of risperidone and preparation method thereof |
| CN103298459A (en) * | 2010-09-23 | 2013-09-11 | 莫诺索尔克斯有限公司 | Method and system for forming a pharmaceutical product directly onto a packaging surface |
| CN102048730A (en) * | 2010-12-10 | 2011-05-11 | 浙江昂利康制药有限公司 | Levamlodipine besylate composition and preparation method thereof |
| CN103239427A (en) * | 2012-02-13 | 2013-08-14 | 刘毅佳 | Film agent for dispersing and dissolving in oral cavity |
| CN102657635A (en) * | 2012-05-04 | 2012-09-12 | 上海现代药物制剂工程研究中心有限公司 | Spongy asenapine sublingual film agent with micropores and preparation method thereof |
| CN102920683A (en) * | 2012-06-11 | 2013-02-13 | 江苏豪森药业股份有限公司 | Olanzapine oral instant membrane |
| CN102824333A (en) * | 2012-09-26 | 2012-12-19 | 苏州大学 | Oral quick-dissolving film preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张劲: "《药物制剂技术》", 31 August 2005 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201509009A1 (en) * | 2014-12-11 | 2017-02-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A thin film strip of asenapine |
| US10898449B2 (en) | 2016-12-20 | 2021-01-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US10980753B2 (en) | 2016-12-20 | 2021-04-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US10952959B2 (en) | 2017-01-11 | 2021-03-23 | Ferring B.V. | Fast disintegrating pharmaceutical composition |
| US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN110354106A (en) * | 2019-08-21 | 2019-10-22 | 成都诺和晟泰生物科技有限公司 | A kind of film rapidly-soluble in the oral cavity and preparation method thereof |
| CN110354106B (en) * | 2019-08-21 | 2023-03-24 | 成都诺和晟泰生物科技有限公司 | Film agent capable of being rapidly dissolved in oral cavity and preparation method thereof |
| CN112402398A (en) * | 2020-11-30 | 2021-02-26 | 北京斯利安药业有限公司 | Oral instant film of diphenhydrasol hydrochloride and preparation method thereof |
| CN112402398B (en) * | 2020-11-30 | 2022-07-12 | 北京斯利安药业有限公司 | Oral instant film of diphenhydrasol hydrochloride and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104000800A (en) | Asenapine maleate oral instant membrane and making method thereof | |
| CN102920683B (en) | Olanzapine oral instant membrane | |
| CN103118662B (en) | The method preparing the heterogeneous dosage form of freeze-dried instant | |
| TWI355936B (en) | Uses of palonosetron hydrochloride | |
| WO2018086498A1 (en) | Pharmaceutical composition and application thereof | |
| CN105232532A (en) | Vitamin C and vitamin K, and compositions and application thereof | |
| JP2020203933A (en) | Pharmaceutical composition containing loxoprofen | |
| CN102784169A (en) | In situ gel preparation loaded with Kangfuxin and its preparation method and use | |
| RU2621144C2 (en) | Pharmaceutical form of gemcitabine of large volume for infusion and kit containing formulations | |
| JP5715400B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| JP2011513437A5 (en) | ||
| CN105640916A (en) | Povidone iodine effervescent tablets with anti-microbial, skin-care and anti-inflammation functions and production process of povidone iodine effervescent tablets | |
| CN106309388A (en) | Medicine composition for treating congestive heart failure and preparation method thereof | |
| CN104784157A (en) | Stable Montelukast oral film preparation | |
| CN104825416A (en) | Disulfiram implant and preparation method thereof | |
| CN104739809B (en) | Film of water-insoluble drug of high drug load and preparation method thereof can be provided | |
| CN100536849C (en) | Medicine composition containing theocin-like medicines and vitamin K | |
| TWI419714B (en) | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacture | |
| CN103784426A (en) | Aripiprazole oral membrane and preparation method thereof | |
| CN103877005A (en) | Compound olanzapine subcutaneous implantable sustained-release preparation | |
| CN101120937A (en) | Application of chlorogenic acid in preparing medicine with cervical cancer preventing and treating efficiency | |
| CN108272776A (en) | Amitriptyline Hydrochloride oral quick-dissolving film preparation | |
| CN106491566A (en) | A kind of levo-cetirizine hydrochloride orally dissolving films and preparation method thereof | |
| CN102860997A (en) | Ondansetron oral cavity instant membrane capable of sheltering taste and preparation method thereof | |
| CN104490924A (en) | Sucralfate composition chewable tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140827 |